Misoprostol Tablets 200mcg

Name: Misoprostol Tablets 200mcg
Brand: Guangzhou Sinolead Biotech Co., Ltd.
SKU: 2097575895

Guangdong, ChinaGuangzhou Sinolead Biotech Co., Ltd.

US$0.10

30,000 Boxes

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Dossier

Ctd

Transport Package

Free

Model NO.

200mcg

Specification

100 Tablets/Bottle

Trademark

Sinolead

Origin

China

Company profile

Importers and Exporters

Guangzhou Sinolead Biotech Co., Ltd.

Guangdong, China

Business Type: Manufacturer/Factory, Trading Company, Group CorporationExport Year: 2005-06-16Nearest Port: Guangzhou, Shenzhen, Hong KongAverage Response Time: ≤15hTerms of Payment: T/T, Western Union, Small-amount payment, etc.International Commercial Terms(Incoterms): FOB, CFR, CIF, EXW

AI-Powered supplier vetting

SummaryThe supplier is a pharmaceutical and healthcare product manufacturer with products including glutathione, ceftriaxone sodium, amoxicillin/clavulanate, and customized generics. It reports multiple management, quality, environmental, occupational safety, and pharmaceutical certifications, along with 50 R&D engineers and 50 quality-control staff. Production information confirms several pharmaceutical dosage forms, but does not provide a directly comparable capacity figure. The supplier supports sample-based, flexible, and minor customization, but explicitly lacks ODM services, SDK availability, and recent new-product development. Service procedures exist for supplier approval, assessment, and corrective actions, although records are incomplete; complaint handling has both a clear procedure and follow-up records. It has no overseas warehouse, showroom, agents, branches, or offline trade-show experience. The company states that it has registered hundreds of pharmaceutical and healthcare products worldwide and...

Supplier typeThe supplier is positioned as a pharmaceutical and healthcare manufacturer, with listed products such as injectable ceftriaxone, glutathione, oral suspension, and customized generics. Its stated activities also include supporting product registration and regulatory dossier compliance, indicating a manufacturing-oriented pharmaceutical supplier rather than a general trading-only provider.

CertificationsThe supplier lists a broad range of certifications and management-system standards, including GMP, ISO 9001, ISO 14001, ISO 14000, HACCP, BSCI, OHSAS/OHSMS 18001, and others. The slice identifies certification holdings but does not provide certificate numbers, validity periods, or scope details.

After-Sales capabilityThe supplier has a clear complaint-handling procedure with followed records, and it accepts multiple service quotation and payment terms with stated lead times within 15 working days in both peak and off-season. However, it has no overseas warehouse, showroom, overseas agents or branches, and has no overseas-service country coverage, limiting evidence of localized after-sales support.

R&D capabilityThe supplier reports 50 R&D engineers, but explicitly states that it had no new products during the past year and no available SDK. It also does not provide ODM services, so the evidence shows established R&D staffing but limited demonstrated recent innovation.

Production capacityThe supplier lists production of multiple pharmaceutical products and dosage forms, including tablets, injections, and oral suspension, and identifies pharmaceuticals and customized generics among its product keywords. It also reports 50 quality-control staff, but the provided production-output statement is not a directly usable capacity metric for comparison.

Customization capabilityThe supplier explicitly offers customization from samples, flexible customization, and minor customization. This supports tailored production, although the supplier separately states that it does not provide ODM services.